Status:
COMPLETED
The Effects of LAF237 on Gastric Function in Type 2 Diabetes
Lead Sponsor:
Mayo Clinic
Collaborating Sponsors:
Novartis Pharmaceuticals
Conditions:
Diabetes Mellitus, Non-Insulin-Dependent
Eligibility:
All Genders
35-70 years
Phase:
PHASE3
Brief Summary
Administration of the incretin hormone, Glucagon-Like-Peptide-1 (GLP-1), has been shown to enhance insulin secretion and suppress glucagon secretion in response to meal ingestion. In addition, GLP-1 a...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Type 2 diabetes without microvascular or macrovascular complications treated with diet or up to 2 oral agents
Exclusion
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
February 1 2006
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00952991
Start Date
May 1 2005
End Date
February 1 2006
Last Update
March 23 2011
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Mayo Clinic
Rochester, Minnesota, United States, 55905